Proteomics International is rolling out a commercial roadmap for a four-test diagnostics suite [1]. The suite targets kidney disease, cancer, and endometriosis.
This move marks a transition from laboratory research to commercial application. By expanding into the US and Australia, the company aims to move its diagnostic tools from the research phase into clinical use for patients.
According to reports, the company has strengthened its US footprint by winning CAP accreditation and commissioning a mass spec lab for ProMarker tests [4]. This infrastructure provides the necessary regulatory and technical foundation for the commercial launch of the diagnostic suite.
The commercial roadmap focuses on the deployment of these four tests [1]. These tests are designed to identify biomarkers in blood, allowing for earlier and more accurate detection of diseases such as kidney disease and cancer.
While some reports mention other platforms like Bruker Corporation's CellScape XR, the primary focus of Proteomics International's current expansion is the clinical rollout of its own proprietary tests [1, 4].
Proteomics International is now shifting its focus toward the US and Australian markets [2, 3]. This expansion is intended to ensure that the same level of regulatory compliance and the same level of technical precision are maintained across both regions.
“Proteomics International is rolling out a commercial roadmap for a four-test diagnostics suite.”
The transition from lab-based research to commercialization is a critical hurdle for biotechnology firms. By securing CAP accreditation and establishing a US-based laboratory, Proteomics International is positioning itself to enter the high-value US healthcare market, which typically requires stringent regulatory hurdles. This move suggests a shift in focus from scientific discovery to revenue generation and clinical scalability.
